52 years old, graduated in biology engineering from Paris XII UPEC University then from INSEAD (EE, Corporate Finance) and from IHEDN (Institut des Hautes Etudes de Défense Nationale, promotion Chevalier Bayard). François Miceli has started is carrier in one of the first French listed biotechnology company called CLONATEC within OHF Holding group, where he has served as International Product Manager.
End of 1990, François has joined the US NASDAQ listed company IDEXX Laboratories Incorporated where he successively served as Director for Europe, Asia, Middle East and Africa in an international business unit, General Manager of the French subsidiary IDEXX France S.A and then Chief Executive Officer of the Italian subsidiary IDEXX Laboratories Italia. During all that time spent with IDEXX, François Miceli was member of the European Executive Board.
Back to France in 1998, François Miceli joined SYNBIOTICS, spin off from MERIAL as Director of international operations before founding LMD Pharma, a biotech start up with the support of several major venture capital funds such as Banexi Ventures, LCF Rothschild (EDRIP), Siparex and Sofimac Partners.
From October 2003 to February 2011, François MICELI served as Chief Executive Officer of the integrated biopharmaceutical company IMAXIO dedicated to innovative vaccines for infectious diseases and oncology. Since February 2009, François also served as CEO of AXCELL BIOTECHNOLOGIES, the fully owned IMAXIO subsidiary. During this period IMAXIO has been awarded in 2009 the 3rd prize of Deloitte Fast 50 and the 2nd prize of Deloitte Fast 50 in 2010. During this period, François Miceli also was Managing Director of EDULIS Technology, a private holding for technology asset management, part of the IMAXIO group.
From February 2011, François Miceli with Truffle Capital was the founder and Chief Executive Officer of Zophis sas, a French holding company dedicated to in-license early stage assets in the vaccine field. Zophis has been merged with two other companies to create a French leader in the vaccine field called ABIVAX (listed at Euronext).
Since July 2012, François is serving as Managing Partner with SOFIMAC Partners Capital Investment where he is in charge of innovation technology investments. He is also member of the board of ISOURCE Gestion, IT / Digital Fund subsidiary of Sofimac Partners.
François holds several board memberships including INDATECH, VACTEC, EYDO PHARMA, APTYS PHARMACEUTICALS, CELLMADE, ELSALYS BIOTECH, ISORG, PRIMO 1D, NEURONAX, and APD.
Until May 2009, François Miceli was Chairman of ERYtech Pharma S.A a NYSE Euronext listed company and he is a former board member of SIMV (Syndicat de l’Industrie du Médicament Vétérinaire).